ST人福(600079.SH)：RFUS-188注射液进入II期临床试验研究

智通财经08-20 15:51

智通财经APP讯，ST人福(600079.SH)发布公告，公司控股子公司宜昌人福药业有限责任公司(简称“宜昌人福”，公司持有其80%的股权)近日在国家药品监督管理局药物临床试验登记与信息公示平台公示了RFUS-188注射液II期临床试验登记信息。

试验名称：评价RFUS-188注射液用于腹部手术术后镇痛的多中心、随机、双盲、平行、安慰剂/阳性对照、两阶段设计的疗效和安全性临床试验试验目的：(1)探索RFUS-188注射液用于术后镇痛的有效剂量(PartA);(2)评价RFUS-188注射液用于术后镇痛的疗效和安全性(PartB)。次要目的：探索RFUS-188注射液重复给药用于术后镇痛的PK/PD特征。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2660404348?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-20 15:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2660404348","market":"us","top_or_hot":-1,"title":"ST人福(600079.SH)：RFUS-188注射液进入II期临床试验研究","media":"智通财经","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/600079\">ST人福</a>(600079.SH)发布公告，公司控股子公司宜昌人福药业有限责任公司(简称“宜昌人福”，公司持有其80%的股权)近日在国家药品监督管理局药物临床试验登记与信息公示平台公示了RFUS-188注射液II期临床试验登记信息。</p><p>试验名称：评价RFUS-188注射液用于腹部手术术后镇痛的多中心、随机、双盲、平行、安慰剂/阳性对照、两阶段设计的疗效和安全性临床试验试验目的：(1)探索RFUS-188注射液用于术后镇痛的有效剂量(PartA);(2)评价RFUS-188注射液用于术后镇痛的疗效和安全性(PartB)。次要目的：探索RFUS-188注射液重复给药用于术后镇痛的PK/PD特征。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ST人福(600079.SH)：RFUS-188注射液进入II期临床试验研究</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nST人福(600079.SH)：RFUS-188注射液进入II期临床试验研究\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/600079\">ST人福</a>(600079.SH)发布公告，公司控股子公司宜昌人福药业有限责任公司(简称“宜昌人福”，公司持有其80%的股权)近日在国家药品监督管理局药物临床试验登记与信息公示平台公示了RFUS-188注射液II期临床试验登记信息。</p><p>试验名称：评价RFUS-188注射液用于腹部手术术后镇痛的多中心、随机、双盲、平行、安慰剂/阳性对照、两阶段设计的疗效和安全性临床试验试验目的：(1)探索RFUS-188注射液用于术后镇痛的有效剂量(PartA);(2)评价RFUS-188注射液用于术后镇痛的疗效和安全性(PartB)。次要目的：探索RFUS-188注射液重复给药用于术后镇痛的PK/PD特征。</p></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.zhitongcaijing.com/content/detail/1482539.html\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBBQ","symbol_name":"Invesco Nasdaq Biotechnology ETF","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1482539.html","article_id":"2660404348","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2660404348","pubTimestamp":1787212291,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，ST人福 发布公告，公司控股子公司宜昌人福药业有限责任公司近日在国家药品监督管理局药物临床试验登记与信息公示平台公示了RFUS-188注射液II期临床试验登记信息。次要目的：探索RFUS-188注射液重复给药用于术后镇痛的PK/PD特征。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600079":"ST人福","IBBQ":"Invesco Nasdaq Biotechnology ETF","BMED":"iShares Health Innovation Active ETF","MDTX":"Corgi MediaTek 2x Daily ETF","BK0028":"国家队","BK0185":"二线龙头","BK0239":"医药制造","PSYK":"PSYK ETF","BK0096":"民营医院","BK0188":"融资融券","BK0070":"员工持股","BK0012":"证金概念","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF"},"translate_title":"ST Renfu (600079.SH): RFUS-188 injection enters phase II clinical trial study","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600079":1.5,"IBBQ":1.5,"PSYK":1.5,"BMED":1.5,"IBBJ":1.5,"MDTX":1.5},"content_text":"智通财经APP讯，ST人福(600079.SH)发布公告，公司控股子公司宜昌人福药业有限责任公司(简称“宜昌人福”，公司持有其80%的股权)近日在国家药品监督管理局药物临床试验登记与信息公示平台公示了RFUS-188注射液II期临床试验登记信息。试验名称：评价RFUS-188注射液用于腹部手术术后镇痛的多中心、随机、双盲、平行、安慰剂/阳性对照、两阶段设计的疗效和安全性临床试验试验目的：(1)探索RFUS-188注射液用于术后镇痛的有效剂量(PartA);(2)评价RFUS-188注射液用于术后镇痛的疗效和安全性(PartB)。次要目的：探索RFUS-188注射液重复给药用于术后镇痛的PK/PD特征。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2660404348","isCrawlerRequest":true}